ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company's executive
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th
Multiple presentations will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl) in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma ADC Therapeutics SA (NYSE: ADCT)
- Companies to Leverage Lead Product Candidate from IGM's Proprietary IgM Antibody Platform with ZYNLONTA for Novel Combination Therapy in Relapsed/Refractory B Cell NHL - - Phase 1 Trial Expected